MedTrace Logo

The Efficacy and Safety of Azovudine in the Treatment of COVID-19

NCT05675761 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-01-10

No results posted yet for this study

Summary

This study is a prospective, multicenter clinical study. It is intended to discuss the efficacy of starting Azovudine treatment as early as possible for all types of patients of COVID-19, the time of remission of specific symptoms, the proportion of patients with severe diseases, oxygen and conditions, and related adverse reactions, so as to understand the efficacy and safety of Azovudine treatment in all types of COVID-19, and provide real world data support for the treatment of the majority of COVID-19 patients.

Conditions

Interventions

DRUG

Azorubine

Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)

Sponsors & Collaborators

  • Fuzhou General Hospital

    lead OTHER

Principal Investigators

  • zongyang yu, Ph.D · The 900th Hospital of the Joint Logistic Support Force, PLA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-04
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05675761 on ClinicalTrials.gov